Skip to main content
رجوع
Watch Compare

HERON THERAPEUTICS, INC. /DE/

جودة البيانات: 83%
HRTX
Nasdaq Manufacturing Chemicals
KWD 0.85
▲ KWD 0.03 (4.10%)
القيمة السوقية: 154.66 M
السعر
KWD 0.82
القيمة السوقية
154.66 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—

Quick Summary

النقاط الرئيسية

Negative free cash flow of -27.91 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
N/A
ROIC-3.02%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio2.56
Interest Coverage-0.26

التقييم

PE (TTM)
-7.66
أقل من متوسط القطاع (-1.47)
P/B Ratio10.39
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -7.7 -1.5
P/B 10.4 1.6
ROE % — -53.3
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

ETFs Holding This Stock

JSIGX JSIGX
2.58% weight
JSCGX JSCGX
2.58% weight
JMCGX JMCGX
0.80% weight
JMIGX JMIGX
0.80% weight
BRUSX BRUSX
0.35% weight
GDSTX GDSTX
0.06% weight
GDSRX GDSRX
0.06% weight
GCSSX GCSSX
0.06% weight
GCSCX GCSCX
0.06% weight
GCSIX GCSIX
0.06% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -20.20 M
ROE N/A ROA -8.40%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -27.91 M
ROIC -3.02% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.56
Interest Coverage -0.26 Asset Turnover N/A
Working Capital 139.69 M Tangible Book Value 14.89 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -7.66 Forward P/E N/A
P/B Ratio 10.39 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -18.05%
Market Cap 154.66 M Enterprise Value 111.59 M
Per Share
EPS (Diluted TTM) -0.12 Revenue / Share N/A
FCF / Share -0.15 OCF / Share -0.15
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 138.19%
SBC-Adj. FCF -38.79 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -20.20 M -13.58 M -110.56 M -182.02 M -220.68 M
EPS (Diluted) -0.12 -0.09 -0.80 -1.67 —
Gross Profit 113.56 M 105.64 M 61.94 M — —
Operating Income -2.54 M -11.53 M -110.62 M -174.66 M -217.83 M
EBITDA — — — — —
R&D Expenses 12.43 M 16.68 M 55.90 M 107.51 M 130.82 M
SG&A Expenses — — — — —
D&A 2.31 M 2.49 M 2.90 M 2.89 M 3.02 M
Interest Expense 9.61 M 6.03 M 3.87 M 2.47 M 2.41 M
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 255.88 M 233.15 M 222.51 M 250.95 M 305.71 M
Total Liabilities 241.54 M 266.80 M 256.48 M 237.38 M 228.14 M
Shareholders' Equity 14.33 M -33.65 M -33.97 M 13.57 M 77.57 M
Total Debt — — — — —
Cash & Equivalents 28.65 M 25.80 M 28.68 M 15.36 M 90.54 M
Current Assets 238.07 M 209.01 M 188.77 M 205.44 M 254.42 M
Current Liabilities 96.10 M 91.46 M 79.69 M 82.36 M 71.06 M